SA
SIGA

S&P 500, Nasdaq, Russell 2000 below the 200-day average · VIX 35.9 · very high volatility

Overview →

SIGA Technologies is a commercial-stage pharmaceutical company focused on biodefense, with its primary asset being TPOXX (tecovirimat), an FDA-approved antiviral treatment for smallpox and orthopoxviruses including monkeypox. The company operates primarily through government procurement contracts with BARDA (Biomedical Advanced Research and Development Authority) and international health agencies, generating revenue from stockpile purchases and delivery orders rather than traditional commercial pharmaceutical sales. Stock performance is driven by government contract awards, geopolitical biodefense spending priorities, and outbreak-related demand spikes.

HealthcareBiodefense Pharmaceuticalshigh - Fixed R&D and regulatory costs are largely sunk, with minimal variable costs per unit manufactured. Once contracts are secured, incremental production carries extremely high margins (50%+ operating margin), but revenue volatility is substantial due to dependence on discrete government procurement cycles rather than recurring commercial sales.

Business Overview

01US government procurement contracts (BARDA stockpile orders) - estimated 70-80% of revenue
02International government sales (Canada, EU health agencies) - estimated 15-20%
03Commercial sales during outbreak events (monkeypox treatment) - variable, <10%

SIGA generates revenue through multi-year procurement contracts with government agencies that maintain strategic national stockpiles of TPOXX for biodefense preparedness. The business model is characterized by lumpy, contract-driven revenue recognition with high gross margins (77%) due to minimal manufacturing costs once development is complete. Pricing power derives from TPOXX being the only FDA-approved smallpox antiviral, creating a monopolistic position in a government-funded niche market. Revenue timing depends on contract modifications, delivery schedules, and appropriations rather than traditional market demand dynamics.

What Moves the Stock

New BARDA contract awards or modifications (size, duration, pricing terms)

International procurement announcements from NATO allies or WHO-affiliated agencies

Outbreak events involving orthopoxviruses (monkeypox, cowpox) driving emergency use demand

US federal budget appropriations for biodefense and pandemic preparedness programs

Clinical trial results for label expansions or new indications beyond smallpox

Watch on Earnings
Quarterly product revenue from TPOXX deliveries under existing contractsBacklog value and timing of remaining performance obligationsCash position and burn rate given lumpy contract-based revenue modelProgress on international regulatory approvals and procurement discussions

Risk Factors

Single-product dependency on TPOXX creates existential risk if government stockpile strategies shift away from smallpox preparedness or alternative antivirals gain approval

Government budget prioritization risk as biodefense competes with other national security and healthcare spending, particularly during fiscal consolidation periods

Patent expiration risk (key patents expire 2028-2032) could enable generic competition and erode pricing power in government procurement

Emergence of competing orthopoxvirus antivirals in clinical development by larger pharmaceutical companies with superior government relationships

Shift in government procurement strategy toward broader-spectrum antivirals or vaccine-only approaches for smallpox preparedness

Revenue concentration and lumpiness creates cash flow volatility - company must maintain sufficient reserves between major contract awards

Minimal balance sheet risk given zero debt, 9.17x current ratio, and strong cash generation, but working capital needs fluctuate with contract timing

StructuralCompetitiveBalance Sheet

Macro Sensitivity

Economic Cycle

low - Revenue is driven by government biodefense budgets and geopolitical threat assessments rather than GDP growth or consumer spending. Federal appropriations for pandemic preparedness show minimal correlation to economic cycles, though severe fiscal constraints could impact discretionary defense spending.

Interest Rates

Rising rates have moderate negative impact on valuation multiples for this cash-generative, low-growth biodefense stock, as investors discount future contract cash flows more heavily. However, the business itself has minimal interest rate exposure with zero debt and substantial cash reserves ($94M+ based on 9.17x current ratio). Higher rates may marginally increase treasury income on cash holdings.

Credit

Minimal - counterparty risk is limited to US government and sovereign entities with negligible default probability. No reliance on commercial credit markets or consumer financing.

Live Conditions
S&P 500 FuturesRussell 2000 FuturesDow Jones Futures

Profile

value - Attracts deep-value and special situations investors focused on cash-generative, asset-light businesses trading below intrinsic value. The 10% FCF yield, 3.3x EV/EBITDA, and zero debt appeal to value-oriented funds, while biodefense contract optionality provides asymmetric upside. Not suitable for growth investors given -0.9% revenue growth and single-product maturity. Event-driven funds may trade around contract announcements and outbreak catalysts.

high - Stock exhibits significant volatility driven by binary contract announcement outcomes and outbreak-related sentiment swings. Small market cap ($500M) and low float amplify price movements. Recent performance shows 13.6% gain over 3 months but -24% over 6 months, reflecting event-driven trading patterns rather than fundamental business volatility.

Key Metrics to Watch
BARDA contract modification announcements and total obligated value under existing agreements
US federal budget allocations for biodefense and pandemic preparedness (HHS/ASPR appropriations)
International orthopoxvirus outbreak incidence rates (WHO surveillance data)
Quarterly TPOXX delivery volumes and average selling prices under government contracts
Cash and marketable securities balance relative to quarterly operating expenses
Pipeline progress on label expansions or new antiviral candidates beyond TPOXX
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.